Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 22, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 77,418 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on November 17, 2006, and the company was advised of it on November 20, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Key Facts for Investor Verification
- 77,418 Ordinary Shares were transferred from the GSK Trust to employee plan participants on November 17, 2006.
- Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.
- The filing was signed by Victoria Whyte, Authorised Signatory, on November 22, 2006.